Literature DB >> 20210488

Preferential accumulation of 5-aminolevulinic acid-induced protoporphyrin IX in breast cancer: a comprehensive study on six breast cell lines with varying phenotypes.

Stacy R Millon1, Julie H Ostrander, Siavash Yazdanfar, J Quincy Brown, Janelle E Bender, Anita Rajeha, Nirmala Ramanujam.   

Abstract

We describe the potential of 5-aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) fluorescence as a source of contrast for margin detection in commonly diagnosed breast cancer subtypes. Fluorescence intensity of PpIX in untreated and ALA-treated normal mammary epithelial and breast cancer cell lines of varying estrogen receptor expression were quantitatively imaged with confocal microscopy. Percentage change in fluorescence intensity integrated over 610-700 nm (attributed to PpIX) of posttreated compared to pretreated cells showed statistically significant differences between four breast cancer and two normal mammary epithelial cell lines. However, a direct comparison of post-treatment PpIX fluorescence intensities showed no differences between breast cancer and normal mammary epithelial cell lines due to confounding effects by endogenous fluorescence from flavin adenine dinucleotide (FAD). Clinically, it is impractical to obtain pre- and post-treatment images. Thus, spectral imaging was demonstrated as a means to remove the effects of endogenous FAD fluorescence allowing for discrimination between post-treatment PpIX fluorescence of four breast cancer and two normal mammary epithelial cell lines. Fluorescence spectral imaging of ALA-treated breast cancer cells showed preferential PpIX accumulation regardless of malignant phenotype and suggests a useful contrast mechanism for discrimination of residual cancer at the surface of breast tumor margins.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20210488      PMCID: PMC2839804          DOI: 10.1117/1.3302811

Source DB:  PubMed          Journal:  J Biomed Opt        ISSN: 1083-3668            Impact factor:   3.170


  49 in total

1.  Preliminary evaluation of two fluorescence imaging methods for the detection and the delineation of basal cell carcinomas of the skin.

Authors:  S Andersson-Engels; G Canti; R Cubeddu; C Eker; C af Klinteberg; A Pifferi; K Svanberg; S Svanberg; P Taroni; G Valentini; I Wang
Journal:  Lasers Surg Med       Date:  2000       Impact factor: 4.025

2.  Endogenous production of protoporphyrin IX induced by 5-aminolevulinic acid in leukemia cells.

Authors:  J Y Chen; N Q Mak; N H Cheung; R N Leung; Q Peng
Journal:  Acta Pharmacol Sin       Date:  2001-02       Impact factor: 6.150

3.  Can autofluorescence demarcate basal cell carcinoma from normal skin? A comparison with protoporphyrin IX fluorescence.

Authors:  R Na; I M Stender; H C Wulf
Journal:  Acta Derm Venereol       Date:  2001 Aug-Sep       Impact factor: 4.437

4.  Protoporphyrin IX occurs naturally in colorectal cancers and their metastases.

Authors:  K T Moesta; B Ebert; T Handke; D Nolte; C Nowak; W E Haensch; R K Pandey; T J Dougherty; H Rinneberg; P M Schlag
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

5.  Variant estrogen receptor alpha mRNAs in human breast cancer specimens.

Authors:  S Y Anandappa; R Sibson; A Platt-Higgins; J H Winstanley; P S Rudland; R Barraclough
Journal:  Int J Cancer       Date:  2000-10-15       Impact factor: 7.396

6.  Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection.

Authors:  D Zaak; D Frimberger; H Stepp; S Wagner; R Baumgartner; P Schneede; M Siebels; R Knüchel; M Kriegmair; A Hofstetter
Journal:  J Urol       Date:  2001-11       Impact factor: 7.450

7.  ALA-PDT results in phenotypic changes and decreased cellular invasion in surviving cancer cells.

Authors:  Tsuimin Tsai; Hong Tai Ji; Pei-Chi Chiang; Ruey-Hwang Chou; Wun-Shaing Wayne Chang; Chin-Tin Chen
Journal:  Lasers Surg Med       Date:  2009-04       Impact factor: 4.025

8.  Breast-conservation treatment outcomes: a community hospital's experience.

Authors:  Barbara D Florentine; Neal K Kaushal; Melissa R Puig; Nayibe Sarda; Greg Senofsky; Brian T Cooper; Alexander Black; Robert Zimmerman; John Barstis
Journal:  Breast J       Date:  2008-12-13       Impact factor: 2.431

9.  Noninvasive measurement of aminolevulinic acid-induced protoporphyrin IX fluorescence allowing detection of murine glioma in vivo.

Authors:  Summer L Gibbs-Strauss; Julia A O'Hara; P Jack Hoopes; Tayyaba Hasan; Brian W Pogue
Journal:  J Biomed Opt       Date:  2009 Jan-Feb       Impact factor: 3.170

10.  Photodynamic diagnosis of breast tumours after oral application of aminolevulinic acid.

Authors:  D P Ladner; R A Steiner; J Allemann; U Haller; H Walt
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

View more
  12 in total

1.  Inhibition of thioredoxin reductase 1 by porphyrins and other small molecules identified by a high-throughput screening assay.

Authors:  Stefanie Prast-Nielsen; Thomas S Dexheimer; Lena Schultz; William C Stafford; Qing Cheng; Jianqiang Xu; Ajit Jadhav; Elias S J Arnér; Anton Simeonov
Journal:  Free Radic Biol Med       Date:  2011-01-22       Impact factor: 7.376

2.  Current and future clinical applications for optical imaging of cancer: from intraoperative surgical guidance to cancer screening.

Authors:  Costas G Hadjipanayis; Huabei Jiang; David W Roberts; Lily Yang
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

3.  Investigation of LED-based photodynamic therapy efficiency on breast cancer cells.

Authors:  Ali Furkan Kamanlı; Mustafa Zahid Yıldız; Ebru Özyol; Asuman Deveci Ozkan; Elif Sozen Kucukkara; Gamze Guney Eskiler
Journal:  Lasers Med Sci       Date:  2020-06-23       Impact factor: 3.161

4.  Expression of Genes Involved in Porphyrin Biosynthesis Pathway in the Human Renal Cell Carcinoma.

Authors:  Hugo Nóbrega da Rocha Filho; Evelin Caroline da Silva; Flávia R O Silva; Lilia Coronato Courrol; Carlos Henrique de Mesquita; Maria Helena Bellini
Journal:  J Fluoresc       Date:  2015-08-06       Impact factor: 2.217

5.  5-Aminolevulinic acid tumor paint and photodynamic therapy for myxofibrosarcoma: an in vitro study.

Authors:  Shachar Kenan; Haixiang Liang; Howard J Goodman; Andrew J Jacobs; Amanda Chan; Daniel A Grande; Adam S Levin
Journal:  J Orthop Surg Res       Date:  2020-03-05       Impact factor: 2.359

6.  Intraoperative fluorescence imaging with aminolevulinic acid detects grossly occult breast cancer: a phase II randomized controlled trial.

Authors:  Kathryn Ottolino-Perry; Anam Shahid; Stephanie DeLuca; Viktor Son; Mayleen Sukhram; Fannong Meng; Zhihui Amy Liu; Sara Rapic; Nayana Thalanki Anantha; Shirley C Wang; Emilie Chamma; Christopher Gibson; Philip J Medeiros; Safa Majeed; Ashley Chu; Olivia Wignall; Alessandra Pizzolato; Cheryl F Rosen; Liis Lindvere Teene; Danielle Starr-Dunham; Iris Kulbatski; Tony Panzarella; Susan J Done; Alexandra M Easson; Wey L Leong; Ralph S DaCosta
Journal:  Breast Cancer Res       Date:  2021-07-12       Impact factor: 6.466

7.  ABCG2 transporter inhibitor restores the sensitivity of triple negative breast cancer cells to aminolevulinic acid-mediated photodynamic therapy.

Authors:  Pratheeba Palasuberniam; Xue Yang; Daniel Kraus; Patrick Jones; Kenneth A Myers; Bin Chen
Journal:  Sci Rep       Date:  2015-08-18       Impact factor: 4.379

8.  Her2 oncogene transformation enhances 5-aminolevulinic acid-mediated protoporphyrin IX production and photodynamic therapy response.

Authors:  Xue Yang; Pratheeba Palasuberniam; Kenneth A Myers; Chenguang Wang; Bin Chen
Journal:  Oncotarget       Date:  2016-09-06

9.  Fluorescence-based discrimination of breast cancer cells by direct exposure to 5-aminolevulinic acid.

Authors:  Midori Morita; Hideo Tanaka; Yasuaki Kumamoto; Akihiro Nakamura; Yoshinori Harada; Takehiro Ogata; Koichi Sakaguchi; Tetsuya Taguchi; Tetsuro Takamatsu
Journal:  Cancer Med       Date:  2019-08-05       Impact factor: 4.452

10.  Characterization of plasma-derived protoporphyrin-IX-positive extracellular vesicles following 5-ALA use in patients with malignant glioma.

Authors:  Pamela S Jones; Anudeep Yekula; Elizabeth Lansbury; Julia L Small; Caroline Ayinon; Scott Mordecai; Fred H Hochberg; John Tigges; Bethany Delcuze; Alain Charest; Ionita Ghiran; Leonora Balaj; Bob S Carter
Journal:  EBioMedicine       Date:  2019-10-15       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.